• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mepolizumab Treatment in Severe Pediatric Asthma: First Multicentric Real-World Data.

作者信息

Wetzke Martin, Funken Dominik, Ahrens Frank O, Gappa Monika, Hansen Gesine, Koerner-Rettberg Cordula, Koester Holger, Schulze Johannes, Schwerk Nicolaus, Zielen Stefan, Happle Christine

机构信息

Pediatric Ped. Pneumology, Allergology, Neonatology, Hannover Medical School, Hannover, Germany.

Pediatrics, AKK Altona Children's Hospital, Hamburg, Germany.

出版信息

Klin Padiatr. 2022 Sep;234(5):305-308. doi: 10.1055/a-1717-2234. Epub 2022 Mar 22.

DOI:10.1055/a-1717-2234
PMID:35319087
Abstract
摘要

相似文献

1
Mepolizumab Treatment in Severe Pediatric Asthma: First Multicentric Real-World Data.美泊利珠单抗治疗重度小儿哮喘：首个多中心真实世界数据
Klin Padiatr. 2022 Sep;234(5):305-308. doi: 10.1055/a-1717-2234. Epub 2022 Mar 22.
2
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.从奥马珠单抗转换为美泊利珠单抗：来自意大利南部的真实临床经验。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620929231. doi: 10.1177/1753466620929231.
3
Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma.真实世界疗效及对美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘的“超级应答者”特征
Chest. 2020 Aug;158(2):491-500. doi: 10.1016/j.chest.2020.03.042. Epub 2020 Apr 8.
4
Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘真实世界队列患者的疗效和安全性。
J Asthma. 2021 Jan;58(1):79-84. doi: 10.1080/02770903.2019.1658208. Epub 2019 Sep 3.
5
Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.美泊利珠单抗附加疗法在重度嗜酸性粒细胞性哮喘真实世界队列中的应答率、有效性及安全性
J Asthma. 2021 May;58(5):651-658. doi: 10.1080/02770903.2020.1723623. Epub 2020 Feb 12.
6
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.多中心西班牙哮喘患者嗜酸性粒细胞分层的美泊利珠单抗真实世界疗效和安全性：REDES 研究。
Drugs. 2021 Oct;81(15):1763-1774. doi: 10.1007/s40265-021-01597-9. Epub 2021 Sep 29.
7
Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.美泊利珠单抗治疗重度嗜酸性粒细胞性哮喘：临床标志物和应答时间的真实世界快照。
Expert Rev Respir Med. 2019 Dec;13(12):1205-1212. doi: 10.1080/17476348.2019.1676734. Epub 2019 Oct 16.
8
Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.美泊利单抗对重度哮喘急性加重的影响：来自美国保险理赔数据库的结果
Allergy Asthma Proc. 2020 Sep 1;41(5):341-347. doi: 10.2500/aap.2020.41.200043.
9
Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.真实世界中奥马珠单抗和美泊利单抗治疗的难治性哮喘表型及其临床结局。
Clin Exp Allergy. 2021 Aug;51(8):1019-1032. doi: 10.1111/cea.13882. Epub 2021 May 6.
10
Mepolizumab: First Global Approval.美泊利珠单抗：全球首次获批
Drugs. 2015 Dec;75(18):2163-9. doi: 10.1007/s40265-015-0513-8.

引用本文的文献

1
Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature.美泊利珠单抗治疗重度小儿哮喘：基于单中心经验及文献综述的肯定与疑问
Children (Basel). 2024 Jul 25;11(8):895. doi: 10.3390/children11080895.
2
Early Assessment of Efficacy and Safety of Biologics in Pediatric Allergic Diseases: Preliminary Results from a Prospective Real-World Study.生物制剂在儿童过敏性疾病中的疗效和安全性早期评估：一项前瞻性真实世界研究的初步结果
Children (Basel). 2024 Jan 28;11(2):170. doi: 10.3390/children11020170.
3
Severe Pediatric Asthma Therapy: Mepolizumab.
重度小儿哮喘治疗：美泊利单抗。
Front Pediatr. 2022 Jul 1;10:920066. doi: 10.3389/fped.2022.920066. eCollection 2022.